BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 33016540)

  • 1. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
    Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany.
    Canbay A; Kachru N; Haas JS; Meise D; Ozbay AB; Sowa JP
    Ann Transl Med; 2021 Apr; 9(8):615. PubMed ID: 33987313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
    Anstee QM; Targher G; Day CP
    Nat Rev Gastroenterol Hepatol; 2013 Jun; 10(6):330-44. PubMed ID: 23507799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
    Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
    Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States.
    Nyberg LM; Cheetham TC; Patton HM; Yang SJ; Chiang KM; Caparosa SL; Stern JA; Nyberg AH
    Hepatol Commun; 2021 Jan; 5(1):83-96. PubMed ID: 33437903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
    Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
    J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
    Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S
    Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Le MH; Le DM; Baez TC; Dang H; Nguyen VH; Lee K; Stave CD; Ito T; Wu Y; Yeo YH; Ji F; Cheung R; Nguyen MH
    Clin Mol Hepatol; 2024 Apr; 30(2):235-246. PubMed ID: 38281814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).
    Stepanova M; Rafiq N; Makhlouf H; Agrawal R; Kaur I; Younoszai Z; McCullough A; Goodman Z; Younossi ZM
    Dig Dis Sci; 2013 Oct; 58(10):3017-23. PubMed ID: 23775317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
    Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
    Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.